Dalia ElGamal, PhD, is an assistant professor in the UNMC Eppley Institute for Research in Cancer and Allied Diseases. Research in the ElGamal laboratory aims to:

• Understand the pathogenesis of B-cell malignancies.
• Evaluate novel targeted therapies for incurable leukemias and lymphomas such as chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
• Establish novel therapeutic approaches to reverse inherent immune defects, with the overall aim of translating effective therapies to the clinic.

Specifically, our lab explores the dynamic interplay between malignant B-cells and their tumor microenvironment (e.g., stroma and immune components), extending to include the gut microbiome. A wide array of cell-based assays coupled with high-throughput omics approaches are used to elucidate key tumor promoting factors and identify "druggable" targets for therapeutic intervention (single or combined), which are further evaluated utilizing established mouse models of aggressive disease. 

Preclinical studies in the lab are focused on novel anti-cancer agents targeted against key survival and tumor-promoting factors in B-cell malignancies including B-cell receptor kinases, nuclear factor-kappa B pathway,  as well as epigenetic factors such as bromodomain and extra-terminal (BET) family proteins.